The opioid epidemic has resulted in thousands of deaths in people infected with acute hepatitis C (HCV) due to IV drug use. Because many of these people are undiagnosed, especially in high-risk populations, many organs from HCV-positive donors are still being procured. The development of highly effective direct-acting antiviral (DAA) therapy has made it possible to successfully transplant HCV-positive organs into HCV-negative recipients and treat the hepatitis C post transplant.
The Uterus Transplant Program at Baylor University Medical Center at Dallas (Baylor Dallas), part of Baylor Scott & White Health, was one of the first programs in the world to study uterus transplantation and has quickly become the largest program in the world. With 20 transplants and 14 healthy babies, the Baylor Dallas Uterus Transplant Program is now the first in the world to offer uterus transplantation outside of a clinical trial.
Baylor University Medical Center at Dallas, part of Baylor Scott & White Health, recently performed its 200th islet cell transplant in a patient with chronic pancreatitis, making Baylor Dallas one of the four largest islet cell transplant programs in the nation in terms of volume. Baylor Dallas is the only hospital in North Texas that performs these transplants.
Interstitial lung disease or diffuse parenchymal lung disease comprises a large group of more than 150 heterogeneous disorders. As a result, patients with these disorders are a difficult group to treat because many of the therapies are individualized to each patient. The Interstitial Lung Disease Clinic at Baylor University Medical Center, part of Baylor Scott & White Health, provides comprehensive care to patients with ILD.
Baylor University Medical Center is one of the major enrollment centers for two national clinical trials that could impact the field of lung transplantation. Both studies are looking at ways to treat early and established chronic rejection after lung transplant
